Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged BTK
Will Pharmacyclics’ Imbruvica patent lawsuit knock BeiGene’s Brukinsa off the market?

AbbVie’s Pharmacyclics recently sued BeiGene for patent infringement.  Both companies distribute Bruton’s tyrosine kinase (BTK) inhibitors for treatment of, among other indications, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).  Pharmacyclics sells Imbruvica® and BeiGene sells Brukinsa®.  Will Pharmacyclics prevail, and if so, what will it gain?

Read More
Markman AdvisorsZachary Silbersher, Silbersher, Pharmacyclics, AbbVie, $ABBV, ABBV, Imbruvica, Ibrutinib, BeiGene, Brukinsa, lymphocytosis, zanubrutinib, patent, CLL, SLL, chronic lymphocytic leukemia, small lymphocytic lymphoma, leukemia, Bruton’s tyrosine kinase, BTK, BTK inhibitor, inhibitorComment